0001415889-24-010604.txt : 20240409
0001415889-24-010604.hdr.sgml : 20240409
20240409180018
ACCESSION NUMBER: 0001415889-24-010604
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240405
FILED AS OF DATE: 20240409
DATE AS OF CHANGE: 20240409
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DAVIS STEPHEN
CENTRAL INDEX KEY: 0001131146
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 24833738
MAIL ADDRESS:
STREET 1: ACADIA PHARMACEUTICALS INC.
STREET 2: 12830 EL CAMINO REAL, SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
form4-04092024_060410.xml
X0508
4
2024-04-05
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001131146
DAVIS STEPHEN
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO
CA
92130
true
true
false
false
CEO
0
Common Stock
2024-04-05
4
M
0
17333
A
136175
D
Common Stock
2024-04-05
4
M
0
34666
A
170841
D
Common Stock
2024-04-08
4
S
0
8858
17.87
D
161983
D
Common Stock
2024-04-08
4
S
0
17716
17.87
D
144267
D
Restricted Stock Units
2024-04-05
4
M
0
17333
0
D
Common Stock
17333
34667
D
Restricted Stock Units
2024-04-05
4
M
0
34666
0
D
Common Stock
34666
138666
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.775 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.77 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The restricted stock units vest in four equal annual installments beginning April 5, 2023.
Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from April 5, 2022 (the "grant date"); 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
/s/ Jennifer J. Rhodes, Attorney-in-Fact
2024-04-09